Cargando…
Slow train coming: an anti-CCN2 strategy reverses a model of chronic overuse muscle fibrosis
One of the first targets proposed as an anti-fibrotic therapy was CCN2. Proof of its involvement in fibrosis was initially difficult, due to the lack of appropriate reagents and general understanding of the molecular mechanisms responsible for persistent fibrosis. As these issues have been progressi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511481/ https://www.ncbi.nlm.nih.gov/pubmed/32410169 http://dx.doi.org/10.1007/s12079-020-00568-1 |